Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

imiquimod

×

Overview

What is Imiquimod?

Imiquimod Cream 5% is an immune response modifier for topical administration. Each gram contains 50 mg of imiquimod in an off-white oil-in-water vanishing cream base consisting of purified water, oleic acid, white petrolatum, polysorbate 60, glycerin, stearyl alcohol, benzyl alcohol, cetyl alcohol, sorbitan monostearate, xanthan gum, methylparaben, propylparaben.

Chemically, imiquimod is 1-(2-methylpropyl)-1-imidazo[4,5-c]quinolin-4-amine. Imiquimod has a molecular formula of CHN and a molecular weight of 240.3. Its structural formula is:



What does Imiquimod look like?



What are the available doses of Imiquimod?

Imiquimod Cream 5%, is supplied in single-use packets each of which contains 250 mg of the cream, equivalent to 12.5 mg of imiquimod. Imiquimod Cream is supplied in a box of 24 packets.

What should I talk to my health care provider before I take Imiquimod?

How should I use Imiquimod?

Imiquimod Cream is indicated for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults.

The application frequency for Imiquimod Cream is different for each indication.


What interacts with Imiquimod?

Sorry No Records found


What are the warnings of Imiquimod?

Sorry No Records found


What are the precautions of Imiquimod?

Sorry No Records found


What are the side effects of Imiquimod?

Sorry No records found


What should I look out for while using Imiquimod?

None.


What might happen if I take too much Imiquimod?

Topical

The most clinically serious adverse event reported following multiple oral imiquimod doses of >200 mg (equivalent to imiquimod content of >16 packets) was hypotension, which resolved following oral or intravenous fluid administration.


How should I store and handle Imiquimod?

Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].Keep out of reach of children.Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].Keep out of reach of children.Imiquimod cream, 5%, is supplied in single-use packets which contain 250 mg of the cream. Available as: box of 24 packets   . Store at 4° - 25°C (39° - 77°F)         Avoid freezing. Keep out of reach of children.Imiquimod cream, 5%, is supplied in single-use packets which contain 250 mg of the cream. Available as: box of 24 packets   . Store at 4° - 25°C (39° - 77°F)         Avoid freezing. Keep out of reach of children.Imiquimod cream, 5%, is supplied in single-use packets which contain 250 mg of the cream. Available as: box of 24 packets   . Store at 4° - 25°C (39° - 77°F)         Avoid freezing. Keep out of reach of children.Imiquimod cream, 5%, is supplied in single-use packets which contain 250 mg of the cream. Available as: box of 24 packets   . Store at 4° - 25°C (39° - 77°F)         Avoid freezing. Keep out of reach of children.


×

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

The mechanism of action of imiquimod cream in treating AK lesions is unknown.

Non-Clinical Toxicology
None.

The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including non-steroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents. When such drugs are administered to a patient receiving glyburide, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving glyburide, the patient should be observed closely for loss of control.

Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving glyburide, the patient should be closely observed for loss of control. When such drugs are withdrawn from a patient receiving glyburide, the patient should be observed closely for hypoglycemia.

A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide. The mechanism of action for this interaction is not known.

A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical or vaginal preparations of miconazole is not known.

Intense local inflammatory reactions including skin weeping or erosion can occur after few applications of imiquimod cream and may require an interruption of dosing. . Imiquimod cream has the potential to exacerbate inflammatory conditions of the skin, including chronic graft versus host disease.

Administration of imiquimod cream is not recommended until the skin is completely healed from any previous drug or surgical treatment.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

Rate this treatment and share your opinion


Learn about User Reviews

Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

Effectiveness (required)

This medication has worked for me.




Ease of Use (required)

This medication has been easy for me to use.




Satisfaction (required)

Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
×

Tips

Tips

×

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).